Market Overview

UPDATE: Wedbush Maintains Raptor Pharmaceutical at Outperform as FDA Pushes Back PDUFA Date

Related RPTP
Raptor Announces CEO Succession Plan; Dr. Christopher Starr To Retire As CEO At Year-End 2014, Julie Anne Smith Named President And CEO-Designate
US Stock Futures Edge Lower Ahead Of Housing Data

Wedbush reiterated its Outperform rating and $10 price target on Raptor Pharmaceutical (NASDAQ: RPTP).

Wedbush commented, "RPTP recently announced that the FDA has pushed PROCYSBI (RP103) PDUFA date to April 30 from January 30. Importantly, FDA is not requesting additional studies or information. RP103 is also under review by the EMA, with potential approval anticipated mid-13. … Our launch expectations remain unchanged, and following a recent debt deal, the company has $50 million in cash, which is estimated to be sufficient into profitability."

Raptor Pharmaceutical closed at $5.51 on Friday.

Posted-In: WedbushAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Most Popular

Related Articles (RPTP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free